Association between anlotinib trough plasma concentration and treatment outcomes in advanced non-small-cell lung cancer.

ABSTRACT:

Background

Efficacy and toxicities of anlotinib (ANL) show large inter-patient variation, which may partly be explained by differences in ANL exposure. Exposure-response/toxicities relationship have not been investigated for ANL. Therefore, the aim of the present study was to explore the association between the trough plasma concentration (C_trough) of ANL and treatment outcomes in Chinese patients with advanced non-small cell lung cancer (NSCLC).

Methods

Patients with advanced NSCLC who started third-line or further ANL alone therapy between January 2021 and October 2022. This study examined the ANL C_trough and clinical response evaluation at day 43 after initiation of ANL treatment. We evaluated the association between the ANL C_trough and cl

SUBMITTER: Chen L 

PROVIDER: S-EPMC10020721 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature